Carnitine Shuttle Steps: CPT-1 → Translocase → CPT-2

The carnitine shuttle moves long-chain fatty acids from the cytosol into the mitochondrial matrix, where β-oxidation happens. After long-chain fatty acyl-CoA synthetase activates the fatty acid to fatty acyl-CoA (spending ATP), the shuttle runs in three steps: load (CPT1 on the outer mitochondrial membrane swaps CoA for carnitine), cross (carnitine–acylcarnitine translocase, CACT, carries acylcarnitine through the inner membrane in exchange for free carnitine) and unload (CPT2 on the matrix side swaps carnitine back for CoA). CPT1 is the rate-limiting step, and malonyl-CoA inhibits it.

Carnitine shuttle steps, enzymes and locations

Carnitine shuttle flowchart: fatty acid (cytosol) → acyl-CoA synthetase → fatty acyl-CoA → CPT1 (blocked by malonyl-CoA) → acylcarnitine → CACT → acylcarnitine in the matrix → CPT2 → fatty acyl-CoA → β-oxidation, while freed carnitine exits via CACT.

Mnemonic: CoA can't cross, so carnitine commutes. CPT1 loads, the translocase ferries, CPT2 unloads.

Does the carnitine shuttle need ATP?

The energy is spent at activation, one step before the shuttle itself. Acyl-CoA synthetase splits ATP into AMP and pyrophosphate (PPᵢ), and a pyrophosphatase then hydrolyzes the PPᵢ, so activation consumes the equivalent of 2 ATP. In the standard ATP balance sheet that is the only cost charged to the fatty acid, and complete oxidation of one palmitate still nets 106 ATP (the arithmetic is in beta-oxidation steps, ATP yield and MCAD). The CPT1 and CPT2 transfers and the CACT exchange add nothing to that tally.

Regulation: malonyl-CoA is the brake on CPT1

Malonyl-CoA stops the liver from burning fat while it is making fat. Acetyl-CoA carboxylase (ACC), a biotin-dependent enzyme, turns acetyl-CoA into malonyl-CoA, which is both the substrate for fatty acid synthesis and the inhibitor of CPT1.

• Three "rate-limiting" answers to keep apart: CPT1 for mitochondrial fatty acid oxidation, mitochondrial HMG-CoA synthase for ketogenesis and HMG-CoA reductase for cholesterol synthesis. The full list is in the rate-limiting enzymes table.

Which fatty acids bypass the shuttle?

Chain length decides where and how a fatty acid is oxidized.

• C10 is a gray zone. Berg's Biochemistry calls C8–C10 fatty acids carnitine-independent, but the GeneReviews CACT chapter treats C10 and longer as shuttle-dependent, so some centers give pure C8 oil in CACT deficiency.
• Peroxisomes hand off to mitochondria. Their first β-oxidation step is an oxidase that makes hydrogen peroxide instead of FADH₂, and the shortened products go to mitochondria, bound to carnitine, to finish.
• Peroxisomal disease clue: in X-linked adrenoleukodystrophy, a defective peroxisomal transporter (ALDP, gene ABCD1) lets VLCFAs accumulate, causing neurologic decline and adrenal insufficiency, mostly in males.

From β-oxidation to ketone bodies

Each β-oxidation round (FAD-linked oxidation, hydration, NAD⁺-linked oxidation, thiolysis) shortens the chain by two carbons and releases 1 FADH₂, 1 NADH and 1 acetyl-CoA. In heart and skeletal muscle, that acetyl-CoA enters the TCA cycle to make ATP. In the fasting liver, oxaloacetate is diverted to gluconeogenesis, so acetyl-CoA accumulates and is turned into ketone bodies: thiolase joins two acetyl-CoA, mitochondrial HMG-CoA synthase (the rate-limiting step) adds a third, and HMG-CoA lyase releases acetoacetate, which becomes β-hydroxybutyrate or acetone. Hepatocytes lack thiophorase (succinyl-CoA:acetoacetate CoA transferase), so they export ketones to brain, heart, muscle and kidney. Ketogenesis therefore depends on an open CPT1; the details are in ketogenesis for Step 1.

Why shuttle defects cause hypoketotic hypoglycemia

Fasting exposes any block between a long-chain fatty acid and the matrix, because the liver relies on fatty acid oxidation once glycogen runs low.

• Ketones stay low: without acetyl-CoA from long-chain fats, the liver cannot make enough ketone bodies.
• Glucose falls: acetyl-CoA normally activates pyruvate carboxylase, a gluconeogenic enzyme, so glucose production lags while tissues keep consuming glucose.
• Fat piles up in the liver (steatosis, hepatomegaly), heart (cardiomyopathy, arrhythmia) and skeletal muscle (myopathy).
• Ammonia often rises during crises.

"Hypoketotic" means inappropriately low, not necessarily zero: GeneReviews notes that in MCAD deficiency some ketones can still appear, because long-chain oxidation still works.

Carnitine shuttle and β-oxidation disorders compared

The location of the block predicts the carnitine and acylcarnitine pattern. The inherited disorders below are autosomal recessive.

Primary vs secondary carnitine deficiency

People who eat meat get about three-quarters of their carnitine from food (red meat, poultry, dairy); the rest is made from lysine and methionine, mainly in the liver and kidney. In primary carnitine deficiency, loss of OCTN2 blocks uptake into cells and renal reabsorption, so up to 95% of filtered carnitine can be lost in urine. About half of untreated patients present before age 2 with metabolic crises; the rest typically present at 2–4 years with cardiomyopathy and weakness, and adults can have fatigue, arrhythmias or sudden death. A low free carnitine on a newborn screen can reflect the mother's deficiency. Treatment is lifelong oral L-carnitine.

Among causes of secondary carnitine deficiency, valproate depletes carnitine through urinary loss as valproylcarnitine, reduced renal reabsorption and reduced synthesis; the carnitine loss is linked to microvesicular steatosis and hyperammonemia, and valproate's inhibition of β-oxidation is the likely cause of its liver injury. For an acute overdose with altered mental status, StatPearls suggests IV L-carnitine while ammonia is monitored.

CPT1A vs CPT2: liver versus muscle

CPT1A deficiency is a liver disease because CPT1A is the liver isoform (also expressed in kidney, lymphocytes and fibroblasts); heart and skeletal muscle use CPT1B, so they are usually spared, although renal tubular acidosis can occur. Because the loading step fails, carnitine stays free; GeneReviews cites total serum carnitine of 70–170 µmol/L (normal 25–69).

CPT2 deficiency comes in lethal neonatal, severe infantile and myopathic forms. The myopathic form is the most common and is the most frequent cause of hereditary myoglobinuria. Attacks of myalgia, often with weakness (about 60%) and brown urine from myoglobinuria (about 75%), follow exercise (the commonest trigger), infection or fasting; CK is typically high during attacks, patients are usually well between them, and males are affected more often. The neonatal and infantile forms instead cause hypoketotic hypoglycemia, liver failure, cardiomyopathy and arrhythmias, resembling CACT deficiency.

MCAD and LCHAD: blocks inside the matrix

MCAD deficiency is the most common inherited fatty acid β-oxidation disorder and is on newborn screening in every US state. The shuttle works, so medium-chain intermediates pile up: a prominent C8 (octanoylcarnitine) with raised C8/C2 and C8/C10 ratios, plus urinary hexanoylglycine and suberylglycine. Fasting or common infections trigger crises, binge drinking often does too, and aspirin worsens the disease.

LCHAD and trifunctional protein (TFP) deficiency affect the TFP complex, which carries three long-chain activities (enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, 3-ketoacyl-CoA thiolase). LCHAD deficiency loses only the dehydrogenase; TFP deficiency loses all three. Two complications are unique among FAO disorders: progressive peripheral neuropathy and retinopathy. About half of children with LCHAD deficiency already have retinopathy by age 2; neuropathy usually starts later (median age about 7 years) and starts earlier in TFP deficiency. In 15–25% of pregnancies with an affected fetus, the mother develops HELLP syndrome or acute fatty liver of pregnancy.

Management principles

1. Avoid fasting. Feed infants every 2–3 hours, keep to age-based fasting limits, use bedtime uncooked cornstarch once tolerated (usually from about age 1), and give IV glucose when illness or a procedure forces a fast.
2. Treat a crisis with dextrose, not just fluid. GeneReviews protocols use IV 10% dextrose at about 1.5 times maintenance, even if the first glucose reading is normal, to shut off lipolysis.
3. Use MCT oil when the block is long-chain. In CPT1A, CACT, CPT2, VLCAD and LCHAD/TFP deficiency, medium-chain triglycerides supply fuel that bypasses both the shuttle and the long-chain β-oxidation enzymes, with a high-carbohydrate diet low in long-chain fat. Triheptanoin, a triglyceride of seven-carbon fatty acids, carries an FDA label for molecularly confirmed long-chain FAO disorders.
4. Skip MCT oil in MCAD deficiency. MCT-based formulas and coconut oil are not recommended as a main fat source, although small amounts are not forbidden.
5. Give carnitine where it is the missing piece. It is the specific treatment for primary carnitine deficiency and is used in valproate toxicity. In long-chain FAO disorders practice depends on the defect: GeneReviews recommends it in CACT deficiency, reserves it for clearly low levels in CPT2 deficiency (free and total carnitine well below 10 µmol/L) and LCHAD/TFP deficiency, and lists no carnitine therapy for CPT1A deficiency, where carnitine is already high. In MCAD deficiency its benefit is unproven.
6. Protect the kidneys in CPT2 attacks. Avoid extended fasting and prolonged exercise, treat rhabdomyolysis with IV hydration (dialysis if kidney failure looms), and plan general anesthesia carefully.

Classic exam traps

• Malonyl-CoA inhibits CPT1, the outer-membrane step, not CPT2 or the translocase.
• Two membranes, two transporters: OCTN2 brings carnitine into cells across the plasma membrane; CACT swaps acylcarnitine for carnitine across the inner mitochondrial membrane.
• Read the carnitine profile: high free carnitine points to CPT1A; very low carnitine with urinary wasting to OCTN2; ↑ C16 and C18:1 to CACT or CPT2 (free carnitine low in CACT and severe CPT2, usually normal in myopathic CPT2); ↑ C8 means MCAD; ↑ hydroxylated C16–C18 species mean LCHAD/TFP.
• CPT2 vs McArdle disease: McArdle symptoms start at the beginning of intense exercise, ease with a "second wind" after about 10 minutes of gentle activity, and come with a chronically high CK and a blunted lactate rise on forearm exercise testing; CPT2 attacks come late in prolonged exercise or with fasting or fever, and muscle biopsy is usually normal or shows only slight lipid excess, with no glycogen accumulation.
• Myoglobinuria on a dipstick: positive for blood, but no red cells on microscopy.
• HELLP or AFLP in pregnancy: test the newborn for LCHAD deficiency and other FAO defects.

Worked examples

Vignette 1. A 19-year-old man has had three episodes of muscle pain and dark brown urine, each after hours of hiking or soccer; the latest followed a skipped breakfast. Between episodes his strength and CK are normal. Now CK is markedly elevated, the urine dipstick is positive for blood with no red cells on microscopy, and plasma acylcarnitines show elevated C16 and C18:1 without hydroxylated species or a C14:1 rise. An earlier forearm exercise test showed a normal lactate rise. What is the most likely diagnosis?

Answer: myopathic CPT2 deficiency: CPT2, on the matrix side of the inner mitochondrial membrane, cannot unload long-chain acylcarnitines.

One-line reasoning: recurrent myoglobinuria after prolonged exertion and fasting, normal between attacks, with long-chain acylcarnitines raised; the normal lactate rise and normal CK between attacks argue against McArdle disease.

Vignette 2. A 9-month-old girl becomes lethargic after 2 days of vomiting from gastroenteritis. Glucose is 32 mg/dL, urine ketones are negative, ALT and ammonia are elevated and the liver is enlarged. Heart examination and CK are normal. Total and free carnitine are high, and the ratio of free carnitine to C16 + C18 acylcarnitines is raised. Which step is defective?

Answer: loading by hepatic CPT1 (CPT1A deficiency).

One-line reasoning: a block at the first carnitine step leaves carnitine unused and long-chain acylcarnitines low; CACT or CPT2 blocks would raise long-chain acylcarnitines, OCTN2 deficiency would make carnitine very low, and MCAD deficiency would raise C8.

Key takeaways

• Order: activation (ATP → AMP + PPᵢ), then CPT1 (outer membrane), CACT (inner-membrane antiport) and CPT2 (matrix side).
• CPT1 is rate-limiting; insulin raises malonyl-CoA and closes it, while glucagon lowers malonyl-CoA and opens it.
• Short- and medium-chain fats (such as C8) skip the shuttle; very-long-chain fats start in peroxisomes.
• Most shuttle and β-oxidation defects cause fasting hypoketotic hypoglycemia, but the common myopathic form of CPT2 deficiency presents with exertional myoglobinuria instead; read the carnitine and acylcarnitine pattern to locate the block.
• Avoid fasting, treat crises with dextrose, use MCT oil for long-chain defects (not as the main fat in MCAD deficiency), and give carnitine for OCTN2 deficiency.

More lipid and energy-metabolism reviews are on the biochemistry topic hub.

Sources

• Biochemistry, Fatty Acid Oxidation (StatPearls, NCBI Bookshelf)
• Berg JM, Tymoczko JL, Stryer L. Biochemistry, 5th edition, Section 22.2 (NCBI Bookshelf)
• Foster DW. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest. 2012
• Biochemistry, Ketone Metabolism (StatPearls, NCBI Bookshelf)
• Biochemistry, Ketogenesis (StatPearls, NCBI Bookshelf)
• Biochemistry, Lipolysis (StatPearls, NCBI Bookshelf)
• Biochemistry, Citric Acid Cycle (StatPearls, NCBI Bookshelf)
• Biotin (StatPearls, NCBI Bookshelf)
• Biochemistry, Cholesterol (StatPearls, NCBI Bookshelf)
• Carnitine Deficiency (StatPearls, NCBI Bookshelf)
• Primary Carnitine Deficiency (GeneReviews, NCBI Bookshelf)
• Carnitine Palmitoyltransferase 1A Deficiency (GeneReviews, NCBI Bookshelf)
• Carnitine-Acylcarnitine Translocase Deficiency (GeneReviews, NCBI Bookshelf)
• Carnitine Palmitoyltransferase II Deficiency (GeneReviews, NCBI Bookshelf)
• Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (GeneReviews, NCBI Bookshelf)
• Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency / Trifunctional Protein Deficiency (GeneReviews, NCBI Bookshelf)
• Beta-Oxidation Cycle Disorders — Merck Manual Professional Edition
• Peroxisomal Disorders — Merck Manual Professional Edition
• Valproate Toxicity (StatPearls, NCBI Bookshelf)
• McArdle Disease (Glycogen Storage Disease Type 5) (StatPearls, NCBI Bookshelf)
• Rhabdomyolysis (StatPearls, NCBI Bookshelf)
• Fatty Liver in Pregnancy (StatPearls, NCBI Bookshelf)
• DOJOLVI (triheptanoin) prescribing information (DailyMed)